Serum syndecan-4 is a novel biomarker for patients with chronic heart failure

Journal of Cardiology

Volumn 57, Issue 3, 2011, Pages 325-332

  Takahashi, Rieko ^a   Negishi, Kazuaki ^a   Watanabe, Atai ^a   Arai, Masashi ^a   Naganuma, Fumio ^b   Ohyama, Yoshiaki ^a   Kurabayashi, Masahiko ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Tsurugaya Hospital   (Japan)

Author keywords

Extracellular matrix; Heart failure; Ventricular remodeling

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; GELATINASE A; SYNDECAN 4; TENASCIN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HEART DEATH; HEART EJECTION FRACTION; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HOSPITAL READMISSION; HUMAN; MALE; PREDICTOR VARIABLE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

BIOLOGICAL MARKERS; CHRONIC DISEASE; DEATH, SUDDEN, CARDIAC; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART VENTRICLES; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PATIENT READMISSION; PROGNOSIS; STROKE VOLUME; SYNDECAN-4; TENASCIN; TRANSFORMING GROWTH FACTORS; VENTRICULAR REMODELING;

EID: 79955029797     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2011.01.012     Document Type: Article

References (19)

1. Tkachenko E., Rhodes J.M., Simons M. Syndecans: new kids on the signaling block. Circ Res 2005, 96:488-500.
2. Zimmermann P., David G. The syndecans, tuners of transmembrane signaling. FASEB J 1999, 13:S91-S100.
3. Echtermeyer F., Streit M., Wilcox-Adelman S., Saoncella S., Denhez F., Detmar M., Goetinck P. Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J Clin Invest 2001, 107:R9-R14.
4. Cornelison D.D., Wilcox-Adelman S.A., Goetinck P.F., Rauvala H., Rapraeger A.C., Olwin B.B. Essential and separable roles for Syndecan-3 and Syndecan-4 in skeletal muscle development and regeneration. Genes Dev 2004, 18:2231-2236.
5. Kojima T., Takagi A., Maeda M., Segawa T., Shimizu A., Yamamoto K., Matsushita T., Saito H. Plasma levels of syndecan-4 (ryudocan) are elevated in patients with acute myocardial infarction. Thromb Haemost 2001, 85:793-799.
6. Li J., Brown L.F., Laham R.J., Volk R., Simons M. Macrophage-dependent regulation of syndecan gene expression. Circ Res 1997, 81:785-796.
7. Schiller N.B., Shah P.M., Crawford M., DeMaria A., Devereux R., Feigenbaum H., Gutgesell H., Reichek N., Sahn D., Schnittger I. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989, 2:358-367.
8. Nishimura R.A., Tajik A.J. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone. J Am Coll Cardiol 1997, 30:8-18.
9. Sohn D.W., Chai I.H., Lee D.J., Kim H.C., Kim H.S., Oh B.H., Lee M.M., Park Y.B., Choi Y.S., Seo J.D., Lee Y.W. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol 1997, 30:474-480.
10. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008, 358:2148-2159.
11. Kapoun A.M., Liang F., O'Young G., Damm D.L., Quon D., White R.T., Munson K., Lam A., Schreiner G.F., Protter A.A. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 2004, 94:453-461.
12. de Lemos J.A., McGuire D.K., Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 2003, 362:316-322.
13. Maisel A.S., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Duc P., Omland T., Storrow A.B., Abraham W.T., Wu A.H., Clopton P., Steg P.G., Westheim A., Knudsen C.W., Perez A., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161-167.
14. Suzuki S., Yoshimura M., Nakayama M., Mizuno Y., Harada E., Ito T., Nakamura S., Abe K., Yamamuro M., Sakamoto T., Saito Y., Nakao K., Yasue H., Ogawa H. Plasma level of B-type natriuretic peptide as a prognostic marker after acute myocardial infarction: a long-term follow-up analysis. Circulation 2004, 110:1387-1391.
15. Finsen A.V., Woldbaek P.R., Li J., Wu J., Lyberg T., Tonnessen T., Christenses G. Increased syndecan expression following myocardial infarction indicates a role in cardiac remodeling. Physiol Genomics 2004, 16:301-308.
16. Abhayaratna W.P., Seward J.B., Appleton C.P., Douglas P.S., Oh J.K., Tajik A.J., Tsang T.S. Left atrial size: physiologic determinants and clinical applications. J Am Coll Cardiol 2006, 47:2357-2363.
17. Terasaki F., Okamoto H., Onishi K., Sato A., Shimomura H., Tsukada B., Imanaka-Yoshida K., Hiroe M., Yoshida T., Kitaura Y., Kitabatake A., Study Group for Intractable Diseases by a Grant from the Ministry of Health Labor and Welfare of Japan Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ J 2007, 71:327-330.
18. Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251-259.
19. Maisel A.S., Koon J., Krishnaswamy P., Kazenegra R., Clopton P., Gardetto N., Morrisey R., Garcia A., Chiu A., De Maria A. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001, 141:367-374.